瑞舒伐他汀对2型糖尿病患者低密度脂蛋白胆固醇和超敏C反应蛋白的影响

Effects of Rosuvastatin on LDL-C and hs-CRP in Patients with Type 2 Diabetes Mellitus

目的探讨瑞舒伐他汀对2型糖尿病患者低密度脂蛋白胆固醇(LDL-C)和高敏C反应蛋白(hsCRP)的影响。方法将2型糖尿病患者随机分为A组、B组、C组,分别予以安慰剂、辛伐他汀(20 mg/d)和瑞舒伐他汀(10 mg/d)连续治疗3个月,于治疗前后分别测定患者低密度脂蛋白和超敏C反应蛋白水平。结果 B组、C组治疗后低密度脂蛋白和超敏C反应蛋白水平均低于同组治疗前水平(P<0.05);C组治疗后低密度脂蛋白和超敏C反应蛋白水平均低于A组、B组治疗后水平(P<0.05)。结论瑞舒伐他汀能降低2型糖尿病患者的低密度脂蛋白和超敏C反应蛋白水平且效果优于辛伐他汀,在预防2型糖尿病患者的心血管事件方面可能起到重要作用。

Objective To investigate the effects of rosuvastatin on low density lipoprotein cholesterol（LDL-C） and high sensitivity C-reactive protein（hs-CRP） in the patients with type 2 diabetes mellitus（T2DM）.Methods The patients with T2DM were divided into group A,B and C and given placebo,simvastatin 20 mg and rosuvastatin 10 mg once a day respectively for 3 months.LDL-C and hs-CRP were measured before and after treatment.Results LDL-C and hs-CRP after treatment in the group B and C was lower than those before treatment（P 0.05）.LDL-C and hs-CRP after treatment in the group C was lower than those in the group A and B（P 0.05）.Conclusion Rosuvastatin can reduce both hs-CRP and LDL-C levels in type 2 diabetic patients with better effects than simvastatin and plays an important role in preventing the cardiovascular events.